Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice.
Topical treatment with 3% phosphonoformate of herpes simplex virus type 1 (HSV)-induced skin infections of hairless mice reduced the severity of skin lesions when the treatment was initiated 3 h after virus inoculation in the lumbosacral area or 3 and 24 h after inoculation in the orofacial area. The mortality was significantly reduced in lumbosacral-infected mice and was completely prevented in orofacial-infected mice when the treatment was initiated with a delay of 24 h after virus inoculation. However, phosphonoformate did not prevent the establishment of latent herpes simplex virus type 1 infections in the spinal and trigeminal ganglia, even when treatment was initiated as early as 3 h after infection.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D005561:Formates / Q000627:therapeutic use; D005724:Ganglia; D006561:Herpes Simplex / Q000188:drug therapy*; D051379:Mice; D008819:Mice, Nude; D009422:Nervous System Diseases / Q000209:etiology / Q000517:prevention & control*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D012874:Skin Diseases, Infectious / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors
D000998:Antiviral Agents; D005561:Formates; D009943:Organophosphorus Compounds